Formation of antinuclear and double-strand DNA antibodies and frequency of lupus-like syndrome in anti-TNF-α antibody-treated patients with inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 17, Issue 1, 2011, Pages 91-98

  Beigel, Florian ^a   Schnitzler, Fabian ^a   Paul Laubender, Rüdiger ^b   Pfennig, Simone ^a   Weidinger, Maria ^a   Göke, Burkhard ^a   Seiderer, Julia ^a   Ochsenkühn, Thomas ^a   Brand, Stephan ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

adalimumab; ANA; antinuclear antibodies; dsDNA; inflammatory bowel disease; infliximab; lupus like syndrome

Indexed keywords

ADALIMUMAB; ANTINUCLEAR ANTIBODY; AZATHIOPRINE; CORTICOSTEROID; DOUBLE STRANDED DNA ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; STEROID; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY TITER; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD SALVAGE; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENTERITIS; FATIGUE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTIOUS ARTHRITIS; INJECTION SITE REACTION; JOINT SWELLING; LUPUS LIKE SYNDROME; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; SYMPTOM; T CELL LYMPHOMA; TREATMENT OUTCOME; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; COHORT STUDIES; DNA; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PROGNOSIS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 78650162670     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21362     Document Type: Article

References (28)

1. Jonsdottir T, Forslid J, van Vollenhoven A, et al. Treatment with tumor necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Ann Rheum Dis. 2004; 63: 1075-1078.
2. Charles PJ, Smeenk RJ, De Jong J, et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. 2000; 43: 2383-2390.
3. Vermeire S, Noman M, Van Assche G, et al. Autoimmunity associated with anti-tumor necrosis factor treatment in Crohn's disease: a prospective cohort study. Gastroenterology. 2003; 125: 32-39.
4. Eriksson C, Engstrand S, Sundqvist KG, et al. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF. Ann Rheum Dis. 2005; 64: 403-407.
5. Ferraccioli GF, Assaloni R, Perin A,. Drug-induced systemic lupus erythematosus and TNF-alpha blockers. Lancet. 2002; 360: 645.
6. Costa MF, Said NR, Zimmermann B,. Drug-induced lupus due to anti-tumor necrosis factor alpha agents. Semin Arthritis Rheum. 2008; 37: 381-387.
7. DeBandt M, Sibilia J, Le Loet X, et al. Systemic lupus erythematosus induced by anti-tumor necrosis factor alpha therapy: a French national survey. Arthritis Res Ther. 2005; 7: 545-551.
8. Klapman JB, Ene-Stroescu D, Becker M, et al. A lupus like syndrome associated with infliximab therapy. Inflamm Bowel Dis. 2003; 9: 176-178.
9. Sarzi-Puttini, Ardizzone S, Manzionna G, et al. Infliximab-induced lupus in Crohn's disease: a case report. Dig Liver Dis. 2003; 35: 814-817.
10. R Development Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL 2009.
11. Hanauer SB, Feagan BG, Lichtenstein GR, et al. ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 35: 1541-1549.
12. Hanauer S, Sandborn W, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006; 130: 323-333.
13. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353: 2462-2476. (Pubitemid 41770166)
14. Sandborn WJ, Feagan BG, Stoinov S, et al., PRECISE 1 Study Investigators. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007; 357: 228-238.
15. Moiton MP, Richez C, Dumoulin C, et al. Role of anti-tumour necrosis factor-alpha therapeutic agents in the emergence of infections. Clin Microbiol Infect. 2006; 12: 1151-1153.
16. Crum NF, Lederman ER, Wallace MR,. Infections associated with tumor necrosis factor-alpha antagonists. Medicine (Baltimore). 2005; 84: 291-302.
17. Strangfeld A, Listing J,. Bacterial and opportunistic infections during anti-TNF therapy. Best Pract Res Clin Rheumatol. 2006; 20: 1181-1195.
18. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001 11; 345: 1098-1104.
19. Stokes MB, Foster K, Markowitz GS, et al. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. Nephrol Dial Transplant. 2005; 20: 1400-1406.
20. Hayat SJ, Uppal SS, Narayanan Nampoory MR, et al. Safety and efficacy of infliximab in a patient with active WHO class IV lupus nephritis. Clin Rheumatol. 2007; 26: 973-975.
21. Via CS, Shustov A, Rus V, et al. In vivo neutralization of TNF-alpha promotes humoral autoimmunity by preventing the induction of CTL. J Immunol. 2001 15; 167: 6821-6826.
22. Spillane AP, Xia Y, Sniezek PJ,. Drug-induced lupus erythematosus in a patient treated with adalimumab. J Am Acad Dermatol. 2007; 56 (5 Suppl): S114-116.
23. Kocharla L, Mongey AB,. Is the development of drug-related lupus a contraindication for switching from one TNF alpha inhibitor to another? Lupus. 2008; 18: 169-171.
24. Havel J, Aboutalebi S, Doughty L, et al. Development of systemic lupus erythematosus in a patient with rheumatoid arthritis following treatment conversion of infliximab to adalimumab. J Drugs Dermatol. 2008; 7: 796-798.
25. Beigel F, Jürgens M, Filik L, et al. Severe Legionella pneumonia following infliximab therapy in a Crohn's disease patient. Inflamm Bowel Dis. 2009; 15: 1240-1244.
26. Beigel F, Jürgens M, Subklewe M, et al. Hepatosplenic T-cell lymphoma in a patient with Crohn's disease. Nat Rev Gastroenterol Hepatol. 2009; 6: 433-436.
27. Nancey S, Blanvillain E, Parmentier B, et al. Infliximab treatment does not induce organ-specific or nonorgan-specific autoantibodies other than antinuclear and anti-double-stranded DNA autoantibodies in Crohn's disease. Inflamm Bowel Dis. 2005; 11: 986-991.
28. Garcia-Planella E, DomÈnech E, Esteve-Comas M, et al. Development of antinuclear antibodies and its clinical impact in patients with Crohn's disease treated with chimeric monoclonal anti-TNFalpha antibodies (infliximab). Eur J Gastroenterol Hepatol. 2003; 15: 351-354.